at Oakland, California and other locations
study started
completion around
Principal Investigator
by Caroline Hastings, MD
Headshot of Caroline Hastings
Caroline Hastings



Owing to the rarity, severity, speed of progression and fatal prognosis of infantile and juvenile GM1, there is a limited understanding of overall disease progression and meaningful outcome measures. This study aims to build a natural history data set through collection of a number of clinical, imaging, and laboratory assessments that may be specific predictors of GM1 disease progression and clinical outcome. Having a GM1 natural history data set can inform potential efficacy endpoints and biomarkers for future clinical trials.

This natural history study will follow up to 40 subjects diagnosed with GM1 gangliosidosis (up to 20 infantile (Type 1) and 20 late infantile/juvenile (Type 2)) for up to 3 years. Visits will be conducted every 6 months, during which several procedures will be performed and the data recorded in order to learn about the natural course of the disease, including changes in clinical and neurological assessments and electrophysiologic, imaging and biofluid biomarkers. Study procedures include: physical & neurological exam, blood & urine sample collection, questionnaires & assessments of development, seizure diary, ECHO, ECG, x-ray and ultrasound (if MRI not performed), EEG and genetic testing (if not already done).

The following procedures are subject to local/institutional policies and the medical discretion of the Study Physician: MRI, lumbar puncture (spinal tap) and General anesthesia/sedation (for MRI and LP).


GM1 Gangliosidosis, GM1, GM1 Type 1, GM1 Type 2, GM1 gangliosidosis Type 1, GM1 gangliosidosis Type 2, GM1 natural history study, GM1 gangliosidosis natural history study, Lysosomal Storage Disorders, Lysosomal Disorders, Gangliosidoses


You can join if…

  1. Documentation/ Confirmation of reduced beta-galactosidase enzyme activity in leukocytes
  2. Confirmed diagnosis of infantile or juvenile GM1 gangliosidosis with documentation of GLB1 mutations
  3. Parent/Caregiver capable of providing informed consent (if cognitively able, child to provide assent as well)
  4. Infantile (Type 1) GM1 subjects: Documented symptom onset by 6 months of age with significant hypotonia on exam or history elicited from parent(s)/ caregiver(s)
  5. Juvenile (Type 2) GM1 subjects: Documented symptom onset after 6 months of age OR documented symptom onset prior to 6 months of age without significant hypotonia on exam or elicited from parent(s)/ caregiver(s)

You CAN'T join if...

  1. Enrollment in any other clinical study with an investigational product/ therapy (patients receiving miglustat off-label will be eligible)
  2. Any clinically significant neurocognitive deficit not attributable to GM1 gangliosidosis or a secondary cause that may, in the opinion of the investigator, confound interpretation of study results
  3. Any condition that, in the opinion of the investigator, would put the subject at undue risk or make it unsafe for the subject to participate


  • UCSF Benioff Children's Hospital Oakland accepting new patients
    Oakland California 94610 United States
  • Children's Hospital of Philadelphia accepting new patients
    Philadelphia Pennsylvania 19104 United States

Lead Scientist at UCSF

  • Caroline Hastings, MD
    Dr. Caroline Hastings is a Professor of Pediatrics and is specialty boarded in Pediatric Hematology Oncology. She has been at Children's Hospital Oakland and now UCSF since completion of her training in 1992. Her longevity in the group has allowed for personal and professional growth and development of long-term relationships with her patients.


accepting new patients
Start Date
Completion Date
University of Pennsylvania
Study Type
Expecting 40 study participants
Last Updated